The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety and reactogenicity of mRNA-1647 vaccine in all participants.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical
|Ages Eligible for Study||Min Age: 16 Years - Max Age: 40 Years|
|Sexes Eligible for Study||Female|
|Accepts Healthy Volunteers||Yes|